Lumos Diagnostics Expands FebriDx Test Rollout at WellStreet Urgent Care

MT Newswires Live
04/14

Lumos Diagnostics Holdings (ASX:LDX) has expanded an agreement with WellStreet Urgent Care to roll out its FebriDx rapid point-of-care test to an additional 43 locations from a single initial site, according to a Tuesday filing with the Australian bourse.

The expanded rollout will take place over the next two months, and once it is completed, Lumos expects WellStreet to launch FebriDx at all of the remaining outlets in its network of 163 urgent care locations, per the filing.

The increased volume and enhanced payor visibility from the expanded rollout should also strengthen the company's position in future contract negotiations with other health care providers, Lumos said.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10